Non-Genotoxic Impurities Qualification: A Risk Based and Scientifically Justified Approach

The control and qualification of impurities remain among the most critical aspects in the development and lifecycle management of pharmaceutical products. However, the recently published reflection paper from the European Medicines Agency signals an important evolution in how non-genotoxic impurities should be assessed, justified, and managed during pharmaceutical development. Until recently, qualification of non-genotoxic impurities […]